Condition: Hepatocarcinoma · Lung Cancer · Melanoma · Sponsor: Second Affiliated Hospital of Guangzhou Medical University
This trial was designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by trans-artery/intra-tumor infusion of PD1/PDL1 antibody and/or CTLA4 antibody ipilimumab plus chemotherapeutic drug and to compare their differences.
This description comes directly from the study's public registry record.
Zhenfeng Zhang, MD,PhD · 02034153532 · zhangzhf@gzhmu.edu.cn
Deji Chen, MD,PhD · 02034153532 · chendeji2003@163.com
Always discuss trial participation with your own doctor first.
| The Second Affiliated Hospital of Guangzhou Medical University | Guanzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03755739